Trials / Not Yet Recruiting
Not Yet RecruitingNCT05429515
Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury
Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury: a Prospective Cohort Study
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
In patients with multiple myeloma-related acute kidney injury, compare the renal outcome of chemotherapy combined with HFR-SUPRA to chemotherapy combined with hemodialysis.
Detailed description
In patients with multiple myeloma-related severe acute kidney injury, compare the renal outcome between patients receiving HFR-SUPRA and patients receiving hemodialysis. Both groups of patients receive chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | HFR-SUPRA | HFR-SUPRA everyday for 3 days, then 3 times/week until patients do not require dialysis. |
| PROCEDURE | hemodialysis | hemodialysis everyday for 3 days, then 3 times/week until patients do not require dialysis. |
| DRUG | Chemotherapy | chemotherapy protocol will be made by hematologists. |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2032-07-01
- Completion
- 2032-12-01
- First posted
- 2022-06-23
- Last updated
- 2022-06-23
Source: ClinicalTrials.gov record NCT05429515. Inclusion in this directory is not an endorsement.